MARKET

FATE

FATE

Fate
NASDAQ

Real-time Quotes | Nasdaq Last Sale

76.34
-0.36
-0.47%
After Hours: 76.34 0 0.00% 16:36 05/17 EDT
OPEN
74.49
PREV CLOSE
76.70
HIGH
77.95
LOW
73.62
VOLUME
965.85K
TURNOVER
--
52 WEEK HIGH
121.16
52 WEEK LOW
27.64
MARKET CAP
7.18B
P/E (TTM)
-36.0145
1D
5D
1M
3M
1Y
5Y
Sector Update: Health Care
MT Newswires · 3d ago
Heron defended despite plunge after FDA approval, Aurora earns mixed reactions after Q3 results; and more in today's analyst action
Fate's early stage data look promising: JefferiesFate Therapeutics (FATE) shares shed ~1.4% after the company announced data from an early stage leukemia trial for its natural killer ((NK)) cell programs.Fate
Seekingalpha · 3d ago
Fate Therapeutics' iPSC-Derived Cell Therapies Induce Leukemic Blast Clearance, Show Durable Remissions In AML Patients
Benzinga · 3d ago
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
Zacks.com · 3d ago
--Wedbush Adjusts Price Target on Fate Therapeutics to $71 From $88, Maintains Neutral Rating
MT Newswires · 3d ago
BRIEF-Fate Therapeutics Announces Interim Phase 1 Data For iPSC-derived NK Cell Programs In Relapsed/Refractory Acute Myeloid Leukemia
reuters.com · 4d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Benzinga · 4d ago
Fate Therapeutics Announces Encouraging Interim Phase 1 Data for iPSC-derived NK Cell Programs in Relapsed / Refractory Acute Myeloid Leukemia
4 of 9 Patients in FT516 Monotherapy Study Achieved Objective Response with Complete Leukemic Blast Clearance in the Bone Marrow
GlobeNewswire · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FATE. Analyze the recent business situations of Fate through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 17 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FATE stock price target is 112.00 with a high estimate of 145.00 and a low estimate of 80.00.
EPS
Institutional Holdings
Institutions: 313
Institutional Holdings: 97.94M
% Owned: 104.15%
Shares Outstanding: 94.04M
TypeInstitutionsShares
Increased
63
7.24M
New
31
747.06K
Decreased
62
1.14M
Sold Out
20
226.54K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Non-Executive Chairman/Independent Director
William Rastetter
President/Chief Executive Officer/Director
J. Scott Wolchko
President/Chief Executive Officer/Director
John Wolchko
Non-Executive Vice Chairman/Independent Director
John Mendlein
Chief Financial Officer
Edward Dulac
Senior Vice President
Sarah Cooley
Chief Scientific Officer
Daniel Shoemaker
Vice President
Yu-Waye Chu
General Counsel/Secretary
Cindy Tahl
Other
Bahram Valamehr
Director
Shefali Agarwal
Director
Robert Hershberg
Independent Director
Timothy Coughlin
Independent Director
Robert Epstein
Independent Director
Karin Jooss
Independent Director
Michael Lee
No Data
  • All
  • Financials
  • Insiders
More
About FATE
Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.

Webull offers kinds of Fate Therapeutics Inc stock information, including NASDAQ:FATE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FATE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FATE stock methods without spending real money on the virtual paper trading platform.